Anti-Insulin Growth Factor-1 Receptor (IGF-1R) Antibody (35102)

Anti-Insulin Growth Factor-1 Receptor (IGF-1R) Antibody (35102)

Product No.: 35102

- -
- -
Clone
1H7
Target
Insulin Growth Factor-1 Receptor (IGF-1R)
Formats AvailableView All
Product Type
Monoclonal
Alternate Names
EC 2.7.10.1, Insulin-like growth factor I receptor, IGF-I receptor, CD antigen CD221 [Cleaved into: Insulin-like growth factor 1 receptorα chain; Insulin-like growth factor 1 receptor β chain]
Isotype
Mouse IgG1
Applications
WB
,
inhibits IGF-1 binding

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Mouse
Immunogen
Purified human placental IGF-1 receptors.
Product Concentration
Lot Specific
Formulation
PBS, pH 7.4
State of Matter
Liquid
Product Preparation
Purified by Protein G affinity chromatography
Storage and Handling
These antibodies are stable for at least one (1) year at -20°C to -70°C. Store product in appropriate aliquots to avoid multiple freeze-thaw cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
Use these antibodies in research studies to delineate signal transduction pathways specific for IGF's and for detecting IGF-1 receptors in crude samples. 35101 may be used to immunoprecipitate IGF-1 receptors. 35102 and 35103 can recognize the IGF-1 a subunit on immunoblots.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Mouse Monoclonal Antibody specific to IGF-1 receptor. 35102 inhibits binding of IGF-1 and -2; inhibits cell growth.
Function
Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.; When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.
NCBI Gene Bank ID
UniProt.org
Research Area
Growth Factors, Cytokines, Receptors

References & Citations

Xiong et al. (1992) Proc Natl Acad Sci USA 89: 5356
Li et al. (1993) Biochem Biophys Res Commun 196: 92.
General Western Blot Protocol
inhibits IGF-1 binding

Certificate of Analysis

Formats Available

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.